Dopesick: 1x4
Pseudo-Addiction
Sky-high OxyContin sales are threatened by reports of abuse, prosecutors investigate a claim central to OxyContin marketing, and Finnix begins to question the safety of the drug.
1 - 1First Bottle Oct. 13, 2021
1 - 2Breakthrough Pain Oct. 13, 2021
1 - 3The 5th Vital Sign Oct. 13, 2021
1 - 4Pseudo-Addiction Oct. 20, 2021
1 - 5The Whistleblower Oct. 27, 2021
1 - 6Hammer the Abusers Nov. 03, 2021
1 - 7Black Box Warning Nov. 10, 2021
1 - 8The People vs. Purdue Pharma Nov. 17, 2021